• Primary peritoneal carcinoma usually manifests as abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. (medscape.com)
  • A pelvic imaging study, if there is clinical suspicion of peritoneal carcinoma. (medscape.com)
  • The management of peritoneal carcinoma is similar to that of epithelial cancers of ovarian and fallopian tube, due to similar clinical characteristics. (medscape.com)
  • The purpose of this case-control study was to compare the prognoses of women with stage III mucinous ovarian carcinoma (MOC) who received maximal or optimal cytoreduction followed by paclitaxel plus carboplatin chemotherapy to those of women with stage III serous epithelial ovarian cancer (EOC) treated in the similar manner. (biomedcentral.com)
  • To define molecular and biochemical profiles associated with the duration of progression-free survival in platinum-sensitive recurrent ovarian, peritoneal primary or fallopian tube carcinoma treated with combination chemotherapy with or without bevacizumab followed with or without maintenance bevacizumab therapy in the presence or absence of secondary surgical cytoreduction. (ucsf.edu)
  • After pathologic and immunohistochemistry tests, the diagnosis of fallopian tube carcinoma with peritoneal dissemination was made. (biomedcentral.com)
  • Although a rare occurrence, we should not forget fallopian tube carcinoma in the differential diagnosis of peritoneal carcinomatosis, even in the absence of Latzke's triad. (biomedcentral.com)
  • Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. (nih.gov)
  • Paclitaxel and carboplatin (TC) is a standard treatment for various gynecologic cancers [ 1 - 3 ]. (e-crt.org)
  • To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer. (ucsf.edu)
  • Conclusion Adjuvant vaginal cuff brachytherapy alone without chemotherapy is an appropriate treatment for women with negative peritoneal cytology and small, early-stage clear cell, serous, and mixed endometrial cancer. (bmj.com)
  • We wondered whether the worse prognosis associated with mucinous histology is also valid when age, tumor grade, substage of disease, and extent of RD are matched with serous histology in women with stage III EOC who have undergone primary CRS followed by standard intravenous paclitaxel plus carboplatin chemotherapy. (biomedcentral.com)
  • Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (ucsf.edu)
  • It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer. (ucsf.edu)
  • To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer , peritoneal primary or fallopian tube cancer. (ucsf.edu)
  • To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases quality of life (QOL) in patients with recurrent platinum-sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer, as measured by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) trial outcome index and Rand Short Form (SF)-36 physical functioning scale. (ucsf.edu)
  • Pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal carcinomatosis. (trialstracker.net)
  • Epithelial cancers of ovarian, fallopian tube, and peritoneal origin are known as epithelial ovarian cancer in clinical practice. (medscape.com)
  • In this guide, this group of cancers is referred to as "ovarian/fallopian tube cancer" because peritoneal cancer is relatively rare. (cancer.net)
  • When the term "ovarian cancer" is used, it includes both fallopian tube and peritoneal cancers because it may be unclear where the cancer started. (cancer.net)
  • Just as with ovarian cancer, some peritoneal cancers may begin in the fallopian tubes and spread from the end of the fallopian tube into the peritoneal cavity. (cancer.net)
  • The most common histology-high-grade serous epithelial ovarian cancer-is considered as a single clinical entity along with fallopian tube and peritoneal cancers because of shared clinical features. (merckmanuals.com)
  • Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this study. (inclinicaltrials.com)
  • After abdominopelvic magnetic resonance imaging, she was sent to the Portuguese Oncology Institute of Oporto with the suspicion of peritoneal carcinomatosis of unknown primary tumor. (biomedcentral.com)
  • The GOG 252 authors concluded that the toxicity and patient-reported outcomes support selection of the regimen consisting of IV carboplatin AUC 6 day 1, dose-dense paclitaxel 80 mg/m 2 IV once weekly, and bevacizumab 15 mg/kg IV day 1 given in 3-week cycles. (medscape.com)
  • Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. (uci.edu)
  • BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. (uci.edu)
  • Researchers from University of Pennsylvania find adding bevacizumab to carboplatin-pemetrexed was effective in treating non-squamous non-small cell lung cancer. (nccn.org)
  • PLYMOUTH MEETING, PA [May 23, 2019] - New research from the Abramson Cancer Center at the University of Pennsylvania, published in the May 2019 issue of JNCCN-Journal of the National Comprehensive Cancer Network , uses a large, real-world dataset to demonstrate there is a modest but consistent survival benefit associated with adding bevacizumab to carboplatin-pemetrexed when treating advanced non-squamous non-small cell lung cancer (NSCLC). (nccn.org)
  • Many oncologists were already using carboplatin-pemetrexed-bevacizumab for patients with advanced non-squamous NSCLC, but this study suggests there is indeed an improvement in overall survival when bevacizumab is added. (nccn.org)
  • 2,759 patients (58%) received carboplatin/pemetrexed while 1,965 (42%) received carboplatin/pemetrexed/bevacizumab. (nccn.org)
  • Despite a lack of randomized clinical trial data, carboplatin and pemetrexed in combination with bevacizumab is a regimen that is used for treating naïve patients with advanced non-squamous NSCLC. (nccn.org)
  • Complimentary access to " Comparative Effectiveness of Carboplatin-Pemetrexed With vs Without Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer " is available until August 10, 2019. (nccn.org)
  • This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that has come back. (ucsf.edu)
  • A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. (ucsf.edu)
  • To identify molecular determinants that predict sensitivity or resistance to carboplatin and paclitaxel with or without bevacizumab followed with or without maintenance bevacizumab therapy. (ucsf.edu)
  • Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. (nih.gov)
  • Arises primarily from the surface of serosal cells of the pleural, peritoneal and pericardial cavities and is a highly aggressive neoplasm. (standardofcare.com)
  • METHODS: This three-arm, randomized, controlled, open-label phase II study (ClinicalTrials.gov identifier: NCT03776812) enrolled women with recurrent, platinum-resistant/refractory, high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer, or ovarian carcinosarcoma treated with ≤4 prior chemotherapeutic regimens. (bvsalud.org)
  • Peritoneal carcinomas are divided into primary and secondary peritoneal tumors. (medscape.com)
  • Primary peritoneal carcinomas originate from the cells lining the peritoneum. (medscape.com)
  • Secondary peritoneal carcinomas usually invade locally or metastasize into the peritoneum from adjacent or remote organs. (medscape.com)
  • It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. (biomedcentral.com)
  • Berstein L, Gurney JG: Carcinomas and other malignant epithelial neoplasms. (oncolink.org)
  • CT findings in patients with malignant peritoneal mesotheliomas range from peritoneum-based masses (a so-called "dry" appearance) to ascites, irregular or nodular peritoneal thickening, and an omental mass (a so-called "wet" appearance). (medscape.com)
  • The pathology revealed a malignant neoplasm composed of tubules, papillary structures, ribbons of primitive stratified columnar cells, vesicular nuclei, and high nuclear-cytoplasmic ratio. (biomedcentral.com)
  • Peritoneal mesothelioma accounts for 10-15% of cases.Most patients with malignant pleural mesothelioma present late in the course of their disease, with an asymptomatic early process. (standardofcare.com)
  • Thus, type I (low-grade serous G1, low-grade endometrioid G1/G2, mucinous or clear cell) tumors are associated with corresponding benign ovarian cystic neoplasms, often developing through an intermediate borderline step and have a better prognosis. (spandidos-publications.com)
  • Staging fallopian tube cancer involves the removal of both fallopian tubes and of the ovaries, uterus, cervix, infracolic omentum, and retroperitoneal lymph nodes, in addition to peritoneal washings and peritoneal biopsies. (medscape.com)
  • Standard imaging tests, including ultrasonography and helical CT scans, are notably insensitive for the detection of peritoneal tumors. (medscape.com)
  • To prospectively determine the incidence of carboplatin and paclitaxel hypersensitivity in these patients undergoing retreatment with both agents as first recurrence therapy. (ucsf.edu)
  • The sensitivity of the test results depends on the ability to completely lavage all regions of the peritoneal cavity and to detect cancer cells being shed into the peritoneal cavity by the tumor. (medscape.com)
  • Primary peritoneal cancer has been linked to certain variants of BRCA1/2 . (medscape.com)
  • IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. (medscape.org)
  • Follicular dendritic cell sarcoma (FDCS) is an uncommon neoplasm of mesenchymal stem cell origin whose clinical course displays much variability. (biomedcentral.com)
  • 1 ] and was since classified in the 2008 World Health Organization classification of haematolymphoid neoplasms with tumours of histiocytes and dendritic cells, alongside other dendritic cell tumours including Langerhans cell tumours, interdigitating dendritic cell sarcoma and other rare tumours. (biomedcentral.com)
  • In the phase III JGOG 3016 trial, dose-dense weekly paclitaxel (80 mg/m 2 ) plus 6 area under the curve (AUC) of carboplatin had a better median progression-free survival (PFS) compared with the tri-weekly conventional regimen in ovarian cancer patients (28.0 vs. 17.2 months) [ 9 , 10 ]. (e-crt.org)
  • In another phase III study, MITO-7, the combination of weekly paclitaxel (60 mg/m 2 ) and carboplatin (3 AUC) was better tolerated than the tri-weekly regimen, with favorable quality-of-life scores and reduced frequency of grade 3-4 toxicities [ 11 ]. (e-crt.org)
  • Cohort 1 received 100 mg/m 2 Genexol-PM and 5 area under the curve (AUC) carboplatin, cohort 2 received 120 mg/m 2 Genexol-PM and 5 AUC carboplatin, and cohort 3 received 120 mg/m 2 Genexol-PM and 6 AUC carboplatin. (e-crt.org)
  • Mutation testing by Caris molecular intelligence demonstrated a breast cancer 2 gene mutation and further treatment with carboplatin and veliparib achieved disease stabilisation. (biomedcentral.com)
  • Based on these findings, it was presumed that paclitaxel could be administered on a weekly dosing schedule in combination with carboplatin, which might lead to better tumor response and lower toxicity than the tri-weekly administration. (e-crt.org)
  • In the treatment recommendations below, note that carboplatin is dosed to achieve a targeted area under the curve (AUC), which is defined as the area under the concentration-versus-time curve and expressed in mg/mL/min. (medscape.com)